title: Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
abstract: OBJECTIVE
  Post-treatment prostate biopsy side-effects were evaluated in patients with locally advanced prostate cancer on endocrine therapy alone or combined with radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
  
  
  METHODS
  One-hundred and twenty patients underwent transrectalultrasound-guided biopsy, and were requested to complete a questionnaire on side-effects occurring within 7 days' follow-up.
  
  
  RESULTS
  The questionnaire was returned by 109 patients (91%) (endocrine therapy only 52%, combined endocrine therapy and radiotherapy 48%). Previous therapy had no significant influence on pain, urinary flow, haematuria or haematospermia. Pain at biopsy was reported in 63% (mild, 57%; moderate, 5.6%; severe, one patient) and pain at follow-up in 31% (mild, 27%; moderate, four patients). Haematuria (mean duration 2.2 days) was reported in 41%, and reduced urinary flow in 20% (mild, 18%; severe: four patients; no patient had urinary retention). Haematospermia was scarce. No patient reported urinary tract infection. Rectal bleeding occurred in 18% in the endocrine and 35% in the combined therapy group (p = 0.047), with a mean duration of 1.6 and 2.2 days, respectively (p = 0.031). In logistic regression analysis, a trend towards increased rectal bleeding was found in patients on combined endocrine therapy and radiotherapy (odds ratio 2.4, p = 0.050).
  
  
  CONCLUSIONS
  Patient-reported post-treatment prostate biopsy side-effects were mild and self-limiting.
authors: Department of Oncology and Radiotherapy, St Olav’s Hospital HF, University Hospital of Trondheim, NO-7006 Trondheim, Norway. arne.solberg@ntnu.no
authors: Arne
authors: A
authors: Solberg
authors: Anders
authors: A
authors: Widmark
authors: Ilker
authors: I
authors: Tasdemir
authors: Göran
authors: G
authors: Ahlgren
authors: Anders
authors: A
authors: Angelsen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001706:Biopsy / Q000009:adverse effects*; D003131:Combined Modality Therapy; D004358:Drug Therapy / Q000379:methods*; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006417:Hematuria / Q000453:epidemiology* / Q000209:etiology; D051516:Hemospermia / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D015994:Incidence; D016729:Leuprolide / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000453:epidemiology* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide; D016729:Leuprolide